US Pharma MarketingNew follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.
Source: BioPharma Dive